Clinical Pharmacokinetics of Newer Antiepileptic Drugs: Lamotrigine, Vigabatrin, Gabapentin and Oxcarbazepine

Clinical Pharmacokinetics

Volumn 30, Issue 6, 1996, Pages 403-415

  Elwes, Robert D Cary ^a,b   Binnie, Colin D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; EPILEPSY; GLUCURONIDATION; HUMAN; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; HUMANS; TISSUE DISTRIBUTION; TRIAZINES; VIGABATRIN;

EID: 0029886355     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630060-00001     Document Type: Article

References (100)

1. Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944-7
2. Xie X, Lancaster B, Peakman T, et al. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na channels and with native Na channels in rat hippocampal neurones. Pflugers Arch 1995; 430: 437-46
3. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Epilepsia 1987; 28: 528
4. Miller AA, Wheatley PL, Sawer DA, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986; 27: 483-9
5. Doig MW, Clare RA. Use of thermospray liquid chromatography-mass spectrometry to aid identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr 1991; 554: 181-9
6. Magdalou J, Herber R, Bidault R, et al. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992; 260: 1166-73
7. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine: a new anticonvulsant. Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535-41
8. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987; 1: 194-201
9. Ramsay ER, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191-200
10. Posner J, Holdich T, Orme M, et al. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1: 121-8
11. Richens A. Pharmacokinetics of lamotrigine. In: Richens A, editor. Clinical update on lamotrigine: a novel antiepileptic Agent. Tunbridge Wells: Wells Medical, 1992: 21-7
12. Yau MK, Wargin W. A single dose and steady state pharmakokinetic study of lamictal in healthy male volunteers. London: Wellcome Foundation, 1990: Internal Report No.: THRS/90/0024
13. Binnie CD, van Emde Boas W, Kasteleijn-Nolst Trenité DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248-54
14. Yau MK. Effect of valproate on the pharmacokinetics of lamotrigine at steady state. Epilepsia 1992; 33: S82
15. Rey E, Vauzelle F, Pons G, et al. Pharmacokinetics of lamotrigine in young epileptic children. 5th World Conference of Clinical Pharmacology and Therapy. 1992; Yokohama
16. Wallace SJ. Add-on open trial of lamotrigine in resistant childseizures. Brain Dev 1990; 12: 734
17. Parsons DN, Miles DW. Metabolic studies with BW430C, a novel anticonvulsant. Epilepsia 1984; 25: 656
18. Holditch T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive. Epilepsia 1991; 96 Suppl. 1: S96
19. Warner T, Patsalos PN, Prevett M, et al. Lamotrigine induced carbamazepine toxicity: an interaction with carbamazepine 10,11 epoxide. Epilepsy Res 1992; 11: 147-50
20. Binnie CD, Beimema DJ, Debets RMC, et al. Seven day administration of lamotrigine in epilepsy: add-on trial. Epilepsy Res 1987; 1: 202-8
21. Schapel G, Beran R, Wajdafje-Berkovic S, et al. Double-blind placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. Epilepsia 1991; 32 Suppl. 1: 58
22. Depot M, Powell JR, Messenheimer JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48: 346-55
23. Lippert B, Metcalf BW, Jung MJ, et al. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem 1977 Apr; 74 (3): 441-5
24. Schlechter PJ. Vigabatrin. In: Meldrum BS, Porter R, editors. New anticonvulsant drugs. London: John Libbey, 1986: 265-75
25. Saletu B, Grunberger J, Linzmayer L, et al. Psychophysiological and psychometric studies after manipulating the gaba system by vigabatrin, a GABA-transaminase inhibitor. Int J Psychophysiol 1986; 4: 63-80
26. Besser R, Krämer G, Thümler R. Vigabatrin bei therapie-resistenten Epilepsien. Aktualle Neurol 1989; 16: 89-92
27. Cocito L, Maffini M, Perfumo P, et al. Vigabatrin in complex partial seizures: a long-term study. Epilepsy Res 1989; 3: 160-6
28. Smithers JA, Lang JF, Okerholm RA. Quantitative analysis of vigabatrin in plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr 1985; 341: 232-8
29. Haegele KD, Schlechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986; 40: 581-6
30. Frisk-Holmberg M, Kerth P, Meyer P. Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 1989; 27: 23S-25S
31. Hoke JF, Chi EM, Antony KK, et al. Bioeqivalence and relative bioavailability of vigabatrin. Epilepsia 1991; 32 Suppl. 3: 7
32. Rev E, Pons G, Richard MO, et al. Pharmokinetics of the individual enantiomers of vigabatrin (γ-vinyl GABA) in epileptic children. Br J Clin Pharmacol 1990; 30: 253-7
33. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27: 19S-22S
34. Mumford JP. A profile of vigabatrin. Br J Clin Pract 1988; 42 Suppl. 61: 7-9
35. Ben Menachem E, Persson LI, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindole-acetic acid in patients with complex partial epilepsy. Epilepsy Res 1988; 2: 96-101
36. Riekkinen PJ, Ylinen A, Halonen T, et al. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol 1989; 27: 87S-94S
37. Rimmer EM, Kongola G, Richens A. Inhibition of the enzyme GABA-aminotransferase in human platelets by vigabatrin. Br J Clin Pharmacol 1988; 25: 251-9
38. Haegele KD, Huebert ND, Ebel M, et al. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988; 44: 558-65
39. Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicentre single-blind study with long-term follow-up. Neurology 1987; 37: 184-9
40. Gram L, Klosterkov P, Dam M. γ-vinyl GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand 1983; 68: 34-9
41. Loiseau P, Hardenburg JP, Pestre M, et al. Double-blind placebo controlled trial of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy, Epilepsia 1986; 27: 115-20
42. Luna D, Dulac O, Pajot N, et al. Vigabatrin in the treatment of childhood epilepsies: a single blind placebo-controlled study. Epilepsia 1989; 30: 430-7
43. Matilainen R, Pitkänen, Ruutiainen T, et al. Effect of vigabatrin on epilepsy in mentally retarded patients. Neurology 1988; 38: 743-7
44. Pedersen SA, Klosterkov P, Gram L, et al. Long-term study of gamma-vinyl GABA in the treatment of epilepsy. Acta Neurol Scand 1985; 72: 295-8
45. Rimmer EM, Richens A. Double-blind study of γ-vinyl GABA in patients with refractory epilepsy. Lancet 1984; 28: 189-90
46. Browne TR, Mattson RH, Penry JK, et al. A multicentre study of vigabatrin for drug resistant epilepsy. Br J Clin Pharmacol 1989; 27: 95S-100S
47. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989; 27: 27S-33S
48. Tonini M, Gatti G, Manzo L, et al. Vigabatrin does not affect the intestinal absorption of phenytoin in rat duodeno-jejunal loops in situ. Pharmacol Res 1992; 26: 201-5
49. Gatti G, Bartoli A, Marchielli R, et al. Vigabatrin-induced decrease in phenytoin concentration does not involve change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603-6
50. Sivenius J, Ylinen A, Murros K, et al. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987; 28: 688-92
51. Ben Menachem E, Persson LI, Schlechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989; 27: 79S-85S
52. Arteaga R, Herranz JL, Valdizan EM, et al. Gamma-vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children. Epilepsia 1992; 33: 923-31
53. Loscher W, Fassbender CP, Gram L, et al. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res 1993; 14: 245-55
54. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994; 44 Suppl. 5: S10-S16
55. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of a lack of proportionality between increasing dose and drug levels in plasma. Pharmacol Res 1993; 10: 276-81
56. Welty DF, Schielke GP, Vartanian MG, et al. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res 1993; 16: 175-81
57. Taylor CP. Mechanism of action of new anti-epileptic drugs. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services Limited, 1993: 13-40
58. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-7
59. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double blind, placebo controlled, parallel-group study. Neurology 1993; 43: 2292-8
60. Ramsay ER. Clinical efficacy and safety of gahapentin. Neurology 1994; 44 Suppl. 5: S23-S30
61. Vollmer KO, Anhut H, Thommann P, et al. Parmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Manelis J, Bental E, Loeber JN, et al., editors. Advances in epileptology. New York: Raven Press, 1989; 209-11
62. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993: 41-6
63. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44 Suppl. 5: S17-S22
64. Ben Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res 1992; 11: 45-9
65. Ojemann LM, Friel PN, Ojcmann GA. Gabapentin concentration in human brain. Epilepsia 1988; 29: 694
66. Türck D, Vollmer KO, Bockbrader HN, et al. Dose-linearity of the new anticonvulsant gabapentin after multiple oral doses [abstract]. Eur J Clin Pharmacol 1989; 36: 310
67. Comstock TJ, Sica DA, Blockbrader HN, et al. Gabapentin pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 1990; 30: 862
68. Eldon MA, Underwood BA, Randinitis EJ, et al. Lack of effect of gabapentin on the pharmacokinetics of a norethidrone acetate/etinyl oestradiol containing oral contraceptive. Neurology 1993; 43 Suppl. 4: A307-A308
69. Graves NM, Holmes GB, Leppick IE, et al. Pharmacokinetics of gabapentin in patients treated with phenyloin. Pharmacotherapy 1989; 9: 196
70. Basim M, Uthman EJ, Hammond EJ, et al. Absence of gabapentin and valproate interaction: an evoked potential and pharmacokinetic study. Epilepsia 1990; 31: 645
71. Graves NM, Leppik IE, Wagner ML, et al. Effect of gagapentin on carbamazepine levels. Epilepsia 1990; 31: 644-5
72. Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682-6
73. Sivenius J, Kälviäinen R, Ylinen A, et al. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539-42
74. Busch JA, Radulovic LL, Bockbrader HN, et al. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy adults. Pharmacol Res 1992; 9 Suppl. 10: S315
75. Baltzer V, Schmutz H. Experimental anticonvulsant properties of GP 47 680 and of GP 47 779, its main human metabolite; compounds related to carbamazepine. In: Meinardi H, Rowan AJ, editors. Advances in epileptology. Amsterdam-Lisse: Swets and Zeitlinger, 1977: 295-9
76. McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35 Suppl. 3: S5-S9
77. Houtkooper MA, Lammertsma A, Meyer JWA, et al. Oxcarbabazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987; 28: 693-8
78. Reinikainen KJ, Keränen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-9
79. Dam M, Ekberg R, Løyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
80. Gram L. Clinical experience with oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S21-2
81. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
82. van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal R) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
83. Schwabe S. Clinical development outlook of oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S2-4
84. Theisohn M, Heimann G. Disposition of the antiepileptic oxcarbazepine and it's metabolites in healthy volunteers. Eur J Clin Pharmacol 1982; 22: 541-51
85. Dickinson RG, Hooper WD, Dunstan PR, et al. First dose and steady-state pharmacokinetics of oxcarbazepine and it's 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74
86. Degen PH, Flesch G, Cardot J, et al. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos 1994; 15: 519-26
87. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S10-S13
88. Feldmann KF, Dorhofer JW, Faigle JW, et al. Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers. In: Dam M, Gram L, Penry JK, editors. Advances in epileptology: XII Epilepsy International Symposium; 1980 Sep 6-10; Copenhagen. New York: Raven Press, 1981: 89-96
89. van Heiningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-9
90. Larkin JG, Mckee PJW, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71
91. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependant enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990; 39: 187-8
92. Mckee PJW, Blacklaw J, Forrest G, et al. A double-blind,placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32
93. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbezepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366-8
94. Arnoldussen W, Hulsman J, Rentmeester T. Oxcarbazepine interactive with valproate? A clinical and pharmacokinetic study in several patient groups. Epilepsia 1992; 33 Suppl. 3: 111
95. Rambeck B, May T. Influence of valproate on serum concentrations of 10-hydroxy-carbezepine, the relevant metabolite oxcarbazepine, and their fluctuations during the day in epileptic patients. Epilepsia 1993; 34 Suppl. 2: 161
96. Kraemer G, Tattenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia 1991; 32 Suppl. 1: 70-1
97. Keraenen T, Jolkkonen J, Jensen PK. Oxcarbazepine does not react with cimetidine in healthy volunteers. Acta Neurol Scand 1992; 85: 239-42
98. Mogensen PH, Jorgensen L, Boas J, et al. Effects of dextropropropoxyphene on the steady state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1992; 85: 14-7
99. Kramer G, Tettenborn B, Jensen PK, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992; 33: 65-71
100. Jensen PK, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-52